Abstract | BACKGROUND: METHODS: Patients with PD-associated apathy (Unified Parkinson's Disease Rating Scale [UPDRS] I item 4 [motivation] ≥2 and patient-rated Apathy Scale [AS] ≥14) were randomized 1:1:1 to "low-dose" rotigotine (≤6 mg/24 h for early PD [those not receiving levodopa] or ≤8 mg/24 h for advanced PD [those receiving levodopa]), "high-dose" rotigotine (≤8 mg/24 h for early PD or ≤16 mg/24 h for advanced PD), or placebo, and maintained at optimal/maximal dose for 12 weeks. Coprimary efficacy variables were: change from baseline to End of Maintenance in patient-rated AS and UPDRS II + III total score. Recruitment was stopped after an interim futility analysis; therefore, all p values are exploratory. RESULTS: Of 122 patients randomized, 81.1 % completed the study (placebo, n = 32/40 [80.0 %]; low-dose rotigotine, n = 30/41 [73.2 %]; high-dose rotigotine, n = 37/41 [90.2 %]). No treatment difference was observed in the change in patient-rated AS (least squares mean [95 % confidence interval (CI)] difference: low-dose, 0.04 [-2.42, 2.50], p =0.977; high-dose, -0.22 [-2.61, 2.18], p = 0.859). Rotigotine improved UPDRS II + III total scores versus placebo (least squares mean [95 % CI] treatment difference: low-dose, -7.29 [-12.30, -2.28], p = 0.005; high-dose, -6.06 [-10.90, -1.21], p = 0.015), and the "mood/apathy" domain of the Non-Motor Symptom Scale as rated by the investigator (secondary outcome). The most frequent adverse events in rotigotine-treated patients were application site reactions, somnolence, and nausea. CONCLUSIONS: TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01782222 . Trial registration date: January 30, 2013.
|
Authors | Robert A Hauser, Jaroslaw Slawek, Paolo Barone, Elisabeth Dohin, Erwin Surmann, Mahnaz Asgharnejad, Lars Bauer |
Journal | BMC neurology
(BMC Neurol)
Vol. 16
Pg. 90
(Jun 07 2016)
ISSN: 1471-2377 [Electronic] England |
PMID | 27267880
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antiparkinson Agents
- Dopamine Agonists
- Tetrahydronaphthalenes
- Thiophenes
- Levodopa
- rotigotine
|
Topics |
- Activities of Daily Living
- Adult
- Aged
- Antiparkinson Agents
(administration & dosage)
- Apathy
(drug effects)
- Dopamine Agonists
(administration & dosage)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Levodopa
(therapeutic use)
- Male
- Middle Aged
- Parkinson Disease
(complications, drug therapy)
- Tetrahydronaphthalenes
(administration & dosage)
- Thiophenes
(administration & dosage)
- Transdermal Patch
|